Crossmark

A novel platform for attenuating immune hyperactivity using <scp>EXO‐CD24</scp> in COVID‐19 and beyond

Crossref DOI link: https://doi.org/10.15252/emmm.202215997

Published Online: 2022-07-13

Published Print: 2022-09-07

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Shapira, Shiran

Ben Shimon, Marina

Hay‐Levi, Mori

Shenberg, Gil

Choshen, Guy

Bannon, Lian https://orcid.org/0000-0002-5317-3613
Tepper, Michael

Kazanov, Dina

Seni, Jonathan

Lev‐Ari, Shahar https://orcid.org/0000-0003-0187-9427
Peer, Michael

Boubas, Dimitrios

Stebbing, Justin https://orcid.org/0000-0002-1117-6947
Tsiodras, Sotirios

Arber, Nadir https://orcid.org/0000-0001-5283-6991
License Information

Version of Record valid from 2022-07-13
More Information

Publication History

Received: 2022-03-13

Accepted: 2022-06-27

Published: 2022-07-13